AWM
GPCR icon

Able Wealth Management’s Structure Therapeutics GPCR Stock Holding History

Able Wealth Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14
Closed -$571 – 280
2023
Q4 		$571 Buy
+14
New +$802 ﹤0.01% 548

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Able Wealth Management's GPCR Position: Q1 2024 in Review

Able Wealth Management sold out of Structure Therapeutics (GPCR) in Q1 2024, closing a stake of 14 shares — an estimated $571 sold.

Able Wealth Management first reported a position in GPCR in Q4 2023 and held it in 1 quarter. The position peaked at $571 in Q4 2023. 119 funds tracked by Wall St. Rank hold GPCR as of Q1 2024.

  • Able Wealth Management reported no remaining Structure Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Able Wealth Management sold 14 Structure Therapeutics shares in Q1 2024, an estimated $571.
  • Able Wealth Management first reported a position in Structure Therapeutics in Q4 2023 and held it in 1 quarter.
  • Able Wealth Management's Structure Therapeutics position peaked at $571 in Q4 2023.
  • 119 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.